Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Why CRISPR Therapeutics Stock Rocked the Market Last Month

Key PointsThe FDA-approved drug it helped developed saw a nearly 80% sequential rise in sales.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Tuesday 8 September →